Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia

Abstract Purpose Little is known about the impact of different psychotropic drugs on acute readmission risk, when used concomitantly in a real-life setting. We aimed to investigate the association between acute readmission risk and use of antipsychotic drugs, antidepressants, mood stabilizers, and benzodiazepines in patients with schizophrenia. Methods A cohort study included all patients diagnosed with schizophrenia admitted to a psychiatric acute unit at Haukeland University Hospital in Bergen, Norway, during a 10-year period (N = 663). Patients were followed from discharge until first readmission or censoring. Cox multiple regression analyses were conducted using antipsychotic drugs, antidepressants, mood stabilizers, and benzodiazepines as time-dependent variables, and periods of use and nonuse were compared within individual patients. Adjustments were made for sex, age at index admission, and excessive use of alcohol and illicit substances. Results A total of 410 patients (61.8%) were readmitted during follow-up, and the mean and median times in days to readmission were 709 and 575, respectively. Compared with nonuse, the use of antipsychotic drugs was associated with reduced risk of readmission (adjusted hazards ratio, 0.20; P < 0.01; confidence interval, 0.16–0.24), and the use of benzodiazepines was associated with increased risk of readmission (adjusted hazards ratio, 1.51; P < 0.01; confidence interval, 1.13–2.02). However, no relation to readmission risk was found for the use of antidepressants and mood stabilizers. Conclusions We found that use of benzodiazepines and antipsychotic drugs are inversely associated with acute readmission risk in schizophrenia.

[1]  L. Mehlum,et al.  Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study , 2021, Schizophrenia Research.

[2]  A. Tanskanen,et al.  Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia , 2020, European Journal of Clinical Pharmacology.

[3]  L. Baandrup Polypharmacy in schizophrenia. , 2020, Basic & clinical pharmacology & toxicology.

[4]  Masaru Mimura,et al.  Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms , 2019, Schizophrenia Research.

[5]  M. Olfson,et al.  Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia , 2019, JAMA psychiatry.

[6]  S. Uysal ICD-10-CM Diagnosis Coding for Neuropsychological Assessment. , 2018, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[7]  C. Correll,et al.  What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia? , 2018, World psychiatry : official journal of the World Psychiatric Association.

[8]  I. Laszlovszky,et al.  Negative Symptoms of Schizophrenia: Constructs, Burden, and Management , 2018, Psychotic Disorders - An Update.

[9]  A. Tanskanen,et al.  Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up , 2017, Schizophrenia bulletin.

[10]  A. Tanskanen,et al.  Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia , 2017, JAMA psychiatry.

[11]  Takeshi Inoue,et al.  Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia: a 2-year naturalistic study , 2016, Neuropsychiatric disease and treatment.

[12]  S. Leucht,et al.  Valproate for schizophrenia. , 2016, The Cochrane database of systematic reviews.

[13]  K. Chen,et al.  The readmission rate and medical cost of patients with schizophrenia after first hospitalization — A 10-year follow-up population-based study , 2016, Schizophrenia Research.

[14]  S. Leucht,et al.  Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials , 2013, European Neuropsychopharmacology.

[15]  T. Stroup,et al.  Polypharmacy for schizophrenia , 2013, Current opinion in psychiatry.

[16]  H. Jørgensen,et al.  Time-dependent effect analysis of antipsychotic treatment in a naturalistic cohort study of patients with schizophrenia , 2012, European Psychiatry.

[17]  John M. Davis,et al.  Maintenance treatment with antipsychotic drugs for schizophrenia. , 2012, The Cochrane database of systematic reviews.

[18]  Sarah E Hetrick,et al.  Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. , 2011, Schizophrenia bulletin.

[19]  M. Keshavan,et al.  Schizophrenia, “just the facts” 4. Clinical features and conceptualization , 2009, Schizophrenia Research.

[20]  J. Bartko,et al.  Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use , 2008, PloS one.

[21]  C. Mullins,et al.  Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia , 2008, Schizophrenia Research.

[22]  J. Kane,et al.  Methodological issues in current antipsychotic drug trials. , 2007, Schizophrenia bulletin.

[23]  S. Leucht,et al.  Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. , 2006, The Journal of clinical psychiatry.

[24]  P. Masand,et al.  Polypharmacy in schizophrenia , 2006, International journal of psychiatry in clinical practice.

[25]  L. Teplin,et al.  Crime victimization in adults with severe mental illness: comparison with the National Crime Victimization Survey. , 2005, Archives of general psychiatry.

[26]  M. Knapp,et al.  Relapse in schizophrenia: costs, clinical outcomes and quality of life , 2004, British Journal of Psychiatry.

[27]  R. Kahn,et al.  Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. , 2002, Archives of general psychiatry.

[28]  J. Stephenson Delay in treating schizophrenia may narrow therapeutic window of opportunity. , 2000, JAMA.

[29]  W. H. Wilson Lithium in schizophrenia. , 1986, Hospital & community psychiatry.

[30]  R. Greenstein,et al.  Benzodiazepines in schizophrenia. , 1986, Psychosomatics.

[31]  A. Włodarczyk,et al.  Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. , 2017, Psychiatria Danubina.

[32]  V. Janout,et al.  Epidemiology and risk factors of schizophrenia. , 2016, Neuro endocrinology letters.

[33]  E. Gambrill Evidence-based practice in the field of substance abuse: a book of readings. , 2010 .

[34]  D. Daniel,et al.  Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia , 2003, Neuropsychopharmacology.

[35]  R Giel,et al.  Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. , 1998, Schizophrenia bulletin.

[36]  R. Drake,et al.  Assessing substance use disorder in persons with severe mental illness. , 1996, New directions for mental health services.